Onco Wiki / Rote Flagge

Anamnese der kumulativen Anthracyclin-Exposition ≥ 250 mg/m2 (Doxorubicin-Äquivalent) — Typika...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDRF-IATROGENIC-ANTHRACYCLINE-CARDIO-PREVENTION
ArtWarnhinweis
Statusreviewed 2026-05-18 | pending_clinical_signoff
ErkrankungenDIS-AML
QuellenSRC-NCCN-AML-2025 SRC-NCCN-BCELL-2025 SRC-NCCN-BREAST-2025

Ursprung der Roten Flagge

BegriffsbestimmungHistory of cumulative anthracycline exposure ≥250 mg/m² (doxorubicin equivalent) — typically reached in breast cancer adjuvant AC/EC regimens, lymphoma CHOP/R-CHOP cohorts ≥6 cycles, pediatric ALL/AML induction, sarcoma + germ-cell regimens. Anthracyclines cause dose- dependent cardiotoxicity: irreversible cardiomyocyte loss → cardiomyopathy → heart failure (HF). Lifetime HF incidence rises with cumulative dose: ~5% at 400 mg/m², ~26% at 550 mg/m², ~48% at 700 mg/m² (legacy ANT- exposure cohorts). Modern cardioprotection (dexrazoxane, liposomal doxorubicin, infusion schedule, baseline + serial echo + BNP/troponin) modulate but do not eliminate risk. Concurrent trastuzumab amplifies risk. Anthracyclines are also topoisomerase-II inhibitors — patient ALSO fires RF-IATROGENIC-TOPO2-TAML-PREVENTION for t-AML surveillance. This RF specifically covers cardiac surveillance. Prevention-persona...
Klinische RichtungUntersuchung
KategorieSonstige

Logik auslösen

{
  "any_of": [
    {
      "finding": "anthracycline_cumulative_dose_ge_250_mg_m2",
      "value": true
    },
    {
      "finding": "anthracycline_with_trastuzumab_exposure",
      "value": true
    },
    {
      "finding": "anthracycline_with_chest_radiation_exposure",
      "value": true
    },
    {
      "finding": "pediatric_anthracycline_exposure",
      "value": true
    }
  ],
  "type": "lab_value"
}

Anmerkungen

Präventivpersona RedFlag für Anthracyclin kumulative Dosis ≥ 250 mg/m2. Kardio-Überwachungsfokus (HF/Kardiomyopathie); t-AML-Überwachung überlappt sich durch separate RF-IATROGENIC-TOPO2-TAML-PREVENTION. Echo q1-5y je nach Risikoprofil (ASCO/COG-LTFU-Kadenz). Motorrouten zur PräventionPlan zur Empfehlung von Ausgangs- + Serien-Echo + BNP. STUB bis zur Zwei-Klinik-Co-Lead-Abmeldung pro CHARTER §6.1 dev-mode.

Verwendet von

Anwendungsgebiet

Warnhinweis